Preview

Medical Immunology (Russia)

Advanced search

Increasing protectivity of the smallpox vaccine

https://doi.org/10.15789/1563-0625-IPO-2203

Abstract

At the present time, vast majority of human population lacks immunity against orthopoxvirus infections caused by variola (smallpox), monkeypox, cowpox, or buffalopox viruses. More and more mass outbreaks of orthopoxvirus infections are yearly registered among humans on different continents. To prevent transition of these outbreaks to widespread epidemics, we should develop appropriate immunoprophylaxis strategies. Currently, massive usage of the classic live vaccine based on vaccinia virus is not acceptable, due to its high reactogenicity. Therefore, it is necessary to develop the variants of vaccinia virus with reduced virulence and increased immunogenicity/protectivity. The aim of this work was to study protective effects against a lethal orthopoxvirus infection occuring after low-dose immunization of mice with vaccinia virus variants, i.e., carrying mutant A34R gene causing increased production of extracellular virions, or a A35R gene deletion encoding protein product inhibiting antigen presentation by the major histocompatibility complex class II. The LIVP viral strain used in Russia as a smallpox vaccine, and its recombinant variants (LIVP-A34R*, LIVP-dA35R and LIVP-A34R*-dA35R) were compared with intranasal or intradermal immunization of BALB/c mice at the doses of 105 or 103 PFU. 28 days following administration of viral preparations (experimental groups) or saline (control groups), the mice underwent intravital blood sampling from retroorbital venous sinus. The levels of virion-specific antibodies were determined in individual serum samples by enzyme immunoassay. On the day 30 of experiment, the mice were infected with cowpox virus at a dose of 32 LD50, which caused total death of control mice on days 6-10. In the groups immunized with the studied viruses at a dose of 105 PFU, all the animals survived, regardless of strain, or immunization method. Upon intradermal immunization (103 PFU) of mice immunized with the original LIVP virus, 83% of the animals survived, whereas all mutant strains of the vaccinia virus provided 100% protection of the mice from subsequent cowpox virus infection. Intranasal immunization of mice at a dose of 103 PFU with LIVP strain protected only 33% of animals from lethal infection with cowpox virus, while the mutant strains LIVP-A34R* and LIVP-A34R*-dA35R provided 67% protection, and the LIVP-dA35R strain has resqued 75% of the mice. The studied mutant vaccinia viruses can be considered not only new candidate vaccines against smallpox and other human orthopoxvirus infections, but also as vector platforms for creating live multivalent vaccines against other infectious diseases.

About the Authors

S. N. Shchelkunov
State Research Center for Virology and Biotechnology “Vector”
Russian Federation

PhD, MD (Biology), Professor, Chief Research Associate

630559, Novosibirsk Region, Koltsovo

Phone: 7 (903) 939-94-80

Fax: 7 (383) 336-74-09



A. A. Sergeev
State Research Center for Virology and Biotechnology “Vector”
Russian Federation

PhD (Biology), Leading Research Associate

Koltsovo, Novosibirsk Region



K. A. Titova
State Research Center for Virology and Biotechnology “Vector”
Russian Federation

Junior Research Associate

Koltsovo, Novosibirsk Region



S. A. Pyankov
State Research Center for Virology and Biotechnology “Vector”
Russian Federation

Leading Research Associate

Koltsovo, Novosibirsk Region



S. N. Yakubitskiy
State Research Center for Virology and Biotechnology “Vector”
Russian Federation

Junior Research Associate

Koltsovo, Novosibirsk Region



References

1. Marennikova S.S., Gashnikov P.V., Zhukova O.A., Ryabchikova E.I., Streltsov V.V., Ryazankina O.I., Chekunova E.V., Yanova N.N., Shchelkunov S.N. Biotype and genetic characterization of the isolate of cowpox virus having caused infection in a child. Zhurnal mikrobiologii epidemiologii i immunologii =Journal of Microbiology, Epidemiology and Immunobiology, 1996, no. 4, pp. 6-10. (In Russ.)

2. Shchelkunov S.N., Shchelkunova G.A. We should be prepared to smallpox reemergence. Voprosy virusologii = Problems of Virology, Russian Journal), 2019, Vol. 64, no. 5, pp. 206-214. (In Russ.)

3. Albarnaz J.D., Torres A.A., Smith G.L. Modulating vaccinia virus immunomodulators to improve immunological memory. Viruses, 2018, Vol. 10, e101. doi: 10.3390/v10030101.

4. Belyakov I.M., Earl P., Dzutsev A., Kuznetsov V.A., Lemon M., Wyatt L.S., Snyder J.T., Ahlers J.D., Franchini G., Moss B., Berzofsky J.A. Shared models of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc. Natl. Acad. Sci. USA, 2003, Vol. 100, pp. 9458-9463.

5. Fenner F., Henderson D.A., Arita I., Jezek Z., Ladnyi I.D. Smallpox and its eradication. Geneva: World Health Organization, 1988. 1460 p.

6. Moss B. Smallpox vaccines: targets of protective immunity. Immunol. Rev., 2011, Vol. 239, no. 1, pp. 8-26.

7. Rehm K.E., Roper R.L. Deletion of the gene from modified vaccinia virus Ankara increases immunogenicity and isotype switching. Vaccine, 2011, Vol. 29, pp. 3276-3283.

8. Sanchez-Sampedro L., Perdiguero B., Mejias-Perez E., Garcia-Arriaza J., Di Pilato M., Esteban M. The evolution of poxvirus vaccines. Viruses, 2015, Vol. 7, pp. 1726-1803.

9. Shchelkunov S.N. An increasing danger of zoonotic orthopoxvirus infections. PLoS Pathog., 2013, Vol. 9, e1003756. doi: 10.1371/journal.ppat.1003756.

10. Shchelkunov S.N., Shchelkunova G.A. Genes that control vaccinia virus immunogenicity. Acta Naturae, 2020, Vol. 12, pp. 33-41.

11. Shchelkunov S.N., Yakubitskiy S.N., Bauer T.V., Sergeev A.A., Kabanov A.S., Bulichev L.E., YurganovaI.A., Odnoshevskiy D.A., Kolosova I.V., Pyankov S.A., Taranov O.S. The influence of an elevated production of extracellular enveloped virions of the vaccinia virus on its properties in infected mice. Acta Naturae, 2020, Vol. 12, pp. 120-132.

12. Shchelkunov S.N., Yakubitskiy S.N., Sergeev A.A., Kabanov A.S., Bauer T.V., Bulichev L.E., Pyankov S.A. Effect of the route of administration of the vaccinia virus strain LIVP to mice on its virulence and immunogenicity. Viruses, 2020, Vol. 12, 795. doi: doi.org/10.3390/v12080795.

13. Xu R., Johnson A.J., Liggitt D., Bevan M.J. Cellular and humoral immunity against vaccinia virus infection of mice. J. Immunol., 2004, Vol. 172, pp. 6265-6271.

14. Yakubitskiy S.N., Kolosova I.V., Maksyutov R.A., Shchelkunov S.N. Highly immunogenic variant of attenuated vaccinia virus. Dokl. Biochem. Biophys., 2016, Vol. 466, pp. 35-38.

15. Yu J., Li Y., Zhong M., Yang J., Zhou D., Zhao B., Cao Y., Yan H., Zhang E., Yang Y., Feng Z., Qi X., Yan H. Improved immune response against HIV-1 Env antigen by enhancing EEV production via K151E mutation in the A34R gene of replication-competent vaccinia virus Tiantan. Antiviral Res., 2018, Vol. 153, pp 49-59.


Supplementary files

Review

For citations:


Shchelkunov S.N., Sergeev A.A., Titova K.A., Pyankov S.A., Yakubitskiy S.N. Increasing protectivity of the smallpox vaccine. Medical Immunology (Russia). 2022;24(1):201-206. (In Russ.) https://doi.org/10.15789/1563-0625-IPO-2203

Views: 504


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1563-0625 (Print)
ISSN 2313-741X (Online)